Studies on toxicity of antitubercular drugs namely isoniazid, rifampicin, and pyrazinamide in an in vitro model of HepG2 cell line

Medicinal Chemistry Research

Volumn 20, Issue 9, 2011, Pages 1611-1615

  Singh, Meenakshi ^a   Sasi, Preetha ^a   Rai, Gaurav ^a   Gupta, Vinod H ^a   Amarapurkar, Deepak ^b   Wangikar, Pramod P ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

^b BOMBAY HOSPITAL   (India)

Author keywords

Antitubercular therapy; ATT induced drug hepatotoxicity; Drug metabolizing enzyme; Human hepatocellular liver carcinoma cell line

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

CELL STRAIN HEPG2; CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER TOXICITY; PHASE CONTRAST MICROSCOPY;

EID: 84856209100     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-010-9405-3     Document Type: Conference Paper

References (22)

1. Agal S, Baijal R, Pramanik S, Patel N, Gupte P, Kamani P, Amarapurkar D (2005) Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol 20:1745-1752 (Pubitemid 43961083)
2. Bhadauria S, Singh G, Sinha N, Srivastava S (2007) Isoniazid induces oxidative stress, mitochondrial dysfunction and apoptosis in Hep G2 cells. Cell Mol Biol (Noisy-le-grand) 15:102-114 (Pubitemid 46799697)
3. Caro AA, Cederbaum AI (2004) Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol Toxicol 44:27-42 (Pubitemid 38263832)
4. Facino RF, Carini M (1980) The inhibitory effect of pyrazinamide on microsomal monooxygenase activities is related to the binding to reduced cytochrome P-450. Pharmacol Res Commun 12:523-537
5. Fotakis George JAT (2006) In vitro cytotoxicity assays: Comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol Lett 160:171-177
6. Girling DJ (1978) The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tuberclosis 59:13-32 (Pubitemid 8283038)
7. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, Chang FY, Lee SD (2003) Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37:924-930
8. Kalgutkar AS, Obach RS, Maurer TS (2007) Mechanism-based inactivation of cytochrome P450 enzymes: Chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 8:407-447 (Pubitemid 47603408)
9. McNeill L, Allen M, Estrada C, Cook P (2003) Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: Improved completion rates but more hepatotoxicity. Chest 123:102-106 (Pubitemid 36126720)
10. Nicod L, Viollon C, Regnier A, Jacqueson A, Richert L (1997) Rifampicin and isoniazid increase acetaminophen and isoniazid cytotoxicity in human HepG2 hepatoma cells. Hum Exp Toxicol 16:28-34 (Pubitemid 27047315)
11. Nishimura Y, Kurata N, Sakurai E, Yasuhara H (2004) Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. J Pharmacol Sci 96:293-300 (Pubitemid 40013338)
12. Schaberg T, Rebhan K, Lode H (1996) Risk factors for side-effects of isoniazid, rifampin, pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 9:2026-2030 (Pubitemid 26333539)
13. Shen C, Zhang H, Zhang G, Meng Q (2006) Isoniazid-induced hepatotoxicity in rat hepatocytes of gel entrapment culture. Toxicol Lett 167:66-74 (Pubitemid 44548278)
14. Shen C, Meng Q, Zhang G, Hu W (2008) Rifampicin exacerbates isoniazid-induced toxicity in human but not in rat hepatocytes in tissue-like cultures. Br J Pharmacol 153:784-791 (Pubitemid 351271758)
15. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R (2008) Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. J Gastroenterol Hepatol 23:192-202 (Pubitemid 351257678)
16. Walubo A, Coetsee C, Arti D, Du Plessis JB (2005) The effect of isoniazid containing regimen on CYP2E1 during antituberculosis therapy. Res Commun Mol Pathol Pharmacol 117-118:137-151 (Pubitemid 351359791)
17. WHO-Report, Global Tuberculosis Control (2008) Surveillance planning financing
18. Wu D, Cederbaum AI (1996) Ethanol cytotoxicity to a transfected HepG2 cell line expressing human cytochrome P4502E1. J Biol Chem 271:23914-23919 (Pubitemid 26327366)
19. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D (2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167:1472-1477 (Pubitemid 37363354)
20. Yew WW (2002) Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf 25:111-133 (Pubitemid 34261186)
21. Yew WW, Leung CC (2006) Antituberculosis drugs and hepatotoxicity. Respirology 11:699-707 (Pubitemid 44581433)
22. Yue J, Peng RX, Yang J, Kong R, Liu J (2004) CYP2E1 mediated isoniazid-induced hepatotoxicity in rats. Acta Pharmacol Sin 25:699-704 (Pubitemid 38620698)